Rosetta Genomics Ltd. develops and commercializes microRNA-based and other molecular diagnostics. MicroRNAs are a group of genes that are produced using instructions encoded in DNA. The company offers diagnostic tests, including RosettaGX Cancer Origin, a diagnostic for the identification of metastatic cancer; mi-LUNG, a lung cancer classification test for cytology samples; mi-KIDNEY, a kidney tumor classification test for pathology samples; and RosettaGX Reveal, a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate (FNA) samples. It is also developing RosettaGX Reveal V2, a microRNA-based assay for the diagnosis of indeterminate thyroid FNAs; and tissue-based microRNA biomarkers to develop a test for the risk stratification of patients with non-muscle-invasive bladder cancer. The company distributes its products primarily in Australia, Canada, Greece, India, Israel, New Zealand, Qatar, Romania, Saudi Arabia, Singapore, Turkey, and the United Arab Emirates. Rosetta Genomics Ltd. has a research collaboration agreement with Sheba Medical Center to develop a microRNA-based signature to predict response to Nivolumab. The company was founded in 2000 and is based in Rehovot, Israel.